Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the 2 major sorts of primary liver tumour. Both are increasing in incidence within the UK, within the case of HCC due to the increasing prevalence of chronic disease , particularly caused by alcohol and non-alcoholic liver disease disease. they need a poor overall prognosis due to late presentation and therefore the presence of underlying liver cirrhosis in patients with HCC.
Patients usually present with a liver mass or jaundice. Assessment is primarily radiological by means of computerized tomography and/or resonance imaging. Surgery remains the main curative option for both tumour types; liver transplantation and, rarely, resection are performed for HCC, and surgical resection for cholangiocarcinoma. However, only approximately 20% of those cancers present at a stage when surgery is feasible .
For non-surgical candidates with HCC, there are three potential treatment options: ablation, trans-arterial chemo-embolization and sorafenib or lenvatinib. Chemotherapy for cholangiocarcinoma is restricted to gemcitabine-based systemic chemotherapy. Screening for HCC may be a strategy that would potentially enhance early diagnosis.